乌帕替尼治疗SAPHO综合征五例并文献复习  

Upadacitinib in the treatment of SAPHO syndrome:five cases report and literature review

作　　者：施晓军 李樱子 王露盈 曹凤娇[1] 侯秀娟[1] 李忱[2] SHI Xiaojun;LI Yingzi;WANG Luying;CAO Fengjiao;HOU Xiujuan;LI Chen(Department of Rheumatology,Dongfang Hospital,Beijing University of Chinese Medicine,Beijing 100078,China;Department of Rheumatology,Fangshan Hospital,Beijing University of Chinese Medicine,Beijing 102401,China)

机构地区：[1]北京中医药大学东方医院北京中医药大学东方医院风湿科,北京100078 [2]北京中医药大学房山医院北京中医药大学房山医院风湿科,北京102401

出　　处：《中国麻风皮肤病杂志》2024年第12期862-865,共4页China Journal of Leprosy and Skin Diseases

基　　金：国家自然科学基金面上项目(编号:82374272,82074246);北京市自然科学基金项目(编号:7242229);中央高校基本科研业务费专项资金(编号:2023-JYB-JBZD-008)。

摘　　要：目的:评价乌帕替尼治疗SAPHO综合征的疗效及安全性。方法:回顾性分析我院5例经乌帕替尼治疗的SAPHO综合征患者的临床资料。结果:5例患者均为掌跖脓疱病伴关节炎,其中2例指甲脱落,经司库奇尤单抗、依奇珠单抗、巴瑞替尼治疗无效,改用乌帕替尼治疗后皮损及骨痛症状缓解,无不良反应发生。结论:乌帕替尼可作为治疗SAPHO综合征的一种选择,尤其对多种生物制剂治疗无效的SAPHO综合征。Objective:To evaluate the safety and efficacy of upadacitinib in patients with SAPHO syndrome.Methods:The clinical data of five patients with SAPHO syndrome treated effectively with upadacitinib from January 2021 to June 2023 were retrospectively analyzed.Results:All five patients reported in this paper suffered from palmoplantar pustulosis with arthritic involvement with two presenting with nail loss.All had previously been ineffectively treated with NSAIDs,DMARDs,bisphosphonates,biologics or baricitinib.After switching to treatment with upadacitinib,patients experienced relief of skin lesions and bone pain,and no data of adverse events were found.Conclusions:Upatinib may be an option for the treatment of SAPHO syndrome,especially in cases where treatment with multiple biologics has failed.

关 键 词：SAPHO综合征 乌帕替尼 JAK抑制剂 掌跖脓疱病 

分 类 号：R593.2[医药卫生—内科学]